



Annexon to Participate in Upcoming September Investor Conferences

September 2, 2026

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- [Annexon, Inc.](#) (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

- Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA; and,
- Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY; and,
- H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 1:00 p.m. ET in New York, NY.

Live webcasts of the presentations can be accessed under the 'Events & Presentations' section on the Investors page at [annexonbio.com](#). Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit [annexonbio.com](#).

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:

Beth Keshishian
917-912-7195
beth@bethkeshishian.com